NNC0705-0001

NNC0705-0001 is an investigational drug developed by Novo Nordisk, currently in phase 1 clinical trials. It is being studied as a potential treatment for **chronic systemic inflammation** and is specifically being investigated for **chronic kidney disease**. Chronic systemic inflammation is known to increase the risk of developing cardiometabolic diseases. The first-in-human study aims to assess the safety, pharmacokinetics, and pharmacodynamics of NNC0705-0001 in healthy adults, utilizing both single and multiple ascending doses as well as evaluating the effect of food on its absorption. The route of administration is oral, but no additional mechanistic, molecular, or structural data are publicly available at this time[1][3][9][2][10].